Tirofiban patient counseling information

Revision as of 01:59, 7 February 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{Tirofiban}} {{CMG}}; {{AE}} {{SS}} ==Patient Counseling Information== Advise patients to watch closely for any signs of bleeding or bruising and to report these ...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Tirofiban
AGGRASTAT® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Tirofiban
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Patient Counseling Information

Advise patients to watch closely for any signs of bleeding or bruising and to report these to their health care provider when they occur.

Advise patients to discuss with their health care provider their use of any other medications, including over-the-counter or herbal products prior to AGGRASTAT use.

Patent: www.medicure.com/aggrastat/patents

AGGRASTAT is manufactured for:

MEDICURE INTERNATIONAL, INC.

by:

BAXTER HEALTHCARE CORPORATION

Deerfield, Illinois 60015 USA

Distributed by:

MEDICURE PHARMA, INC. Somerset, NJ 08873 USA 1-800-509-0544 Printed in USA 07-19-72-370

  • Registered trademark of Medicure International Inc.

© 2013 Copyright used under license. All rights reserved. Intravia is a registered trademark of Baxter International Inc.[1]

References

  1. "AGGRASTAT (TIROFIBAN) INJECTION, SOLUTION [MEDICURE INTERNATIONAL INC]". Retrieved 6 February 2014.

Template:WikiDoc Sources